Memantine Grindeks

Memantine hydrochloride, the active ingredient in Memantine Grindeks, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is prescribed to treat cognitive decline associated with Alzheimer’s disease in adult patients. The drug modulates glutamatergic neurotransmission, helping to reduce excitotoxic neuronal damage.

GNH USA supplies Memantine Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable logistics for global distribution.

Memantine is an NMDA receptor antagonist indicated for the treatment of cognitive decline associated with Alzheimer’s disease.

- Alzheimer’s disease (mild to moderate): may improve memory, attention, and daily functioning. - Alzheimer’s disease (severe): may help preserve ability to perform basic self‑care tasks. - Alzheimer’s disease (behavioral symptoms): may reduce agitation and aggression associated with the disease.

Memantine may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Seizures - Severe hypertension - Hepatic injury - Psychotic symptoms

When prescribing memantine, clinicians should consider several safety precautions to minimize risk.

- Renal impairment: adjust dose or monitor renal function closely. - Hepatic disease: use with caution and monitor liver enzymes. - History of seizures: monitor for increased seizure activity. - Concomitant NMDA antagonists: avoid combined use due to additive effects. - Pregnancy and lactation: insufficient data; weigh potential benefits against risks. - Store at room temperature: keep in original packaging, protect from moisture and light.

Memantine can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive CNS effects may exacerbate dizziness or confusion.

Moderate Interactions (Monitor Closely): - Acetylcholinesterase inhibitors (e.g., donepezil): may require dose adjustment. - CNS depressants (e.g., benzodiazepines): monitor for enhanced sedation. - Diuretics (e.g., furosemide): may increase memantine plasma concentrations.